Short answer
A medical device registered in Malaysia must carry its Malaysian registration number on the labelling within six months of registration, and the label must show the device name and model, the lot or serial number where relevant, an expiry or manufacturing date where relevant, and the manufacturer’s and Authorised Representative’s details (MDA/GD/0026, 7th edition, May 2026). Labelling is in English for professional use devices; home use devices need Bahasa Malaysia. Software can use electronic instructions for use for professional users after a documented risk analysis, with a QR code, barcode or URL on the device or its packaging and a clearly labelled help section in the software. The labelling must not mention MDA or the Ministry of Health or use MDA’s logo.
Where the rules come from
Labelling of medical devices in Malaysia is governed by the Medical Device Act 2012 (Act 737) and the Medical Device Regulations 2012. MDA explains the requirements in its guidance document MDA/GD/0026, Requirements for Labelling of Medical Devices, now in its seventh edition dated May 2026. It applies to all medical devices, including IVDs, except those exempted from registration under the Medical Device (Exemptions) Order 2024; promotional materials and brochures are outside its scope. The seventh edition adds definitions for electronic labelling, rules for electronic instructions for use (e-IFU) and accessibility requirements for e-IFU.
In MDA/GD/0026, labelling means the label, the instructions for use and any other information on identification, technical description, intended purpose and proper use of the device, excluding shipping documents. It can be printed or electronic and may accompany the device or direct the user to where it can be accessed, for example a website.
General requirements
- Registration number within six months. A registered device must be labelled with its Malaysian registration number within six months of the registration date. MDA encourages using the QR code from the registration certificate to show it (section 4.1(b)).
- Legible, permanent and prominent labels, in a medium and format suited to the device and its intended users (4.1(d), (e)).
- Residual risks identified in the risk analysis should appear as contraindications or warnings (4.1(g)).
- Same content as registered. Labelling may be applied after import or manufacture but before placing on the market, and its content must be as submitted to MDA in the registration (4.4).
- Location. The registration number, the manufacturer and Authorised Representative details and the QR code, if available, must be where customers and users can see them at the point of sale (4.5(b)).
- Symbols. Internationally recognised symbols are encouraged; where their meaning is not obvious, for example for home use devices, an explanation is required (4.6).
What the label must show
Section 4.8.1 lists the general contents of labelling:
| Item | MDA/GD/0026 requirement |
|---|---|
| Identification | Device name and model |
| Traceability | Batch code or lot number, or serial number, where relevant |
| Dates | Use-by date (at least year and month) where relevant; otherwise, as appropriate, the date of manufacture |
| Local manufacturer and Authorised Representative | Name, address and at least one contact detail (email, phone or website) |
| Foreign manufacturer | Name and address; contact details are optional |
| Technical details and intended purpose | Specifications, contents of the packaging and, where not obvious, the intended purpose |
| Use and safety | Instructions for use; side effects, limitations, warnings and precautions; servicing needs; disposal information where relevant |
The technical details, intended purpose, instructions, warnings, servicing and disposal information may be given in an insert or other labelling after applying risk management according to ISO 14971 (4.8.2). Labelling information must also follow MDA’s Code of Advertisement, MDA/GD/0032 (4.8.3).
The IFU adds warnings and precautions, the clinical benefit to be expected and a summary of safety and clinical performance relevant to the user or patient, and should show its date of issue or latest revision (4.10). For home use devices, where relevant, the IFU should tell the user not to make any decision of medical relevance without first consulting a healthcare provider. IVDs have additional content requirements in section 4.11.
Language and Bahasa Malaysia
- Home use devices need Bahasa Malaysia (4.7(a)). MDA’s labelling FAQ says that all information in the labelling of a home use device must be translated, except brand names, proper nouns and words that are the same in both languages.
- Other devices use English (4.7(b)); other languages may be added as needed.
- Section 4.5(e) adds that, for information provided on the label, the Bahasa Malaysia translation must be on the label itself.
- Adding a Bahasa Malaysia translation does not require a change notification, according to MDA’s FAQ.
A home use device is one intended for use outside a professional healthcare facility by lay persons, including patients, caregivers and family members (3.2). Many SaMD products, such as patient apps, fall here; decision support used only by clinicians usually does not. The classification follows your intended purpose and intended users.
Electronic IFU and e-labelling
The seventh edition sets out when and how instructions can be provided electronically (4.12):
- e-IFU is eligible for devices intended for professional users; for home use devices it depends on the potential risk of using an e-IFU.
- Users must always be able to get the e-IFU on paper on request, without undue delay or within the period set in the risk assessment, and at no extra cost.
- Where the IFU is downloadable, the web address must be printed clearly on the physical label, and the electronic content must be identical to the IFU approved in the registration.
- The manufacturer must document a risk analysis for the e-IFU covering, among other points, the users’ knowledge and means to view it, the use environment, protection against tampering, back-up in case of hardware or software faults, emergencies that need paper information, website or internet unavailability, and version management.
- Changes to electronic labelling follow MDA’s change notification guidance, MDA/GD/0020, and the paper IFU must be revised within a defined time so that both versions stay aligned.
Section 4.13 adds accessibility requirements: accessible digital formats with legible fonts, sufficient contrast and adjustable text size; a direct access mechanism such as a QR code, barcode or URL on the device or its packaging; an e-IFU that can be downloaded or viewed offline; a visible version number or date of issue; a customer support channel for users who cannot access the e-IFU; and protection against unauthorised modification.
Notes for medical device software
MDA/GD/0026 does not have a separate chapter for stand-alone software, but several provisions apply directly:
- In-software instructions. For software or app-based devices that rely on network connectivity, the IFU integrated in the software must be easy to find in a clearly labelled section, such as ‘User Guide’, ‘Instructions’ or ‘Help’, and must stay available during normal use (4.13(c)).
- Display screens and websites. Labelling may be provided through a display screen incorporated into the device and through the manufacturer’s website, targeted to the intended users (4.3).
- Storage media. For medical device software, user instructions may be supplied on electronic storage such as a USB drive (4.10(m)).
- Combinations. Where a device works with other devices, equipment or dedicated software, the labelling must give enough detail for a safe combination (4.9(a)(ix)).
For downloadable software without physical packaging, the guidance does not say where the registration number and Authorised Representative details should appear. In practice, teams place the label content in an ‘About’ screen and at the point of download, and include the approach in the registration dossier, since labelling must match what MDA approved. Agree it with your Authorised Representative before submission. Your EU MDR labelling and IFU are the starting point; the Malaysian additions are mainly the registration number, the AR details, the language rules and the e-IFU documentation.
What not to put on the label
- No statement that MDA, the Ministry of Health or any of its bodies promotes or endorses the device (4.1(c)), and no use of “Medical Device Authority (MDA)” or “Ministry of Health Malaysia” unless required by the Ministry, for example in tender documents (4.14).
- No MDA logo on any labelling (4.15).
- Other regulatory approvals, such as CE marking, may appear on the label, according to MDA’s FAQ.
Over-labelling and changes
- Additional labels with Authorised Representative or importer details, or translations, may be applied, but must not cover the lot or serial number, the date of manufacture or the expiry date, and must stay legible and durable for the shelf life (4.4). MDA’s FAQ confirms that stickers are allowed on that basis.
- For newly registered products, adding the AR details and the registration number to the labelling does not need a change notification; the updated labelling is submitted at re-registration.
- If the Authorised Representative changes, the new AR must relabel existing stock with its own details before placing it on the market.
For the registration route and the Authorised Representative’s role, see our Malaysia MDA registration guide and the GDPMD guide. Labelling adaptation is part of our Malaysia and Singapore registration support.
Sources
- MDA/GD/0026 Requirements for Labelling of Medical Devices, 7th edition (May 2026) — sections 2–4.15 and revision history
- MDA – FAQs: Labelling of Medical Devices — Bahasa Malaysia translation, stickers, CE marking, change notification, change of AR
- MDA – Guidance documents list — MDA/GD/0020, MDA/GD/0032 and other referenced documents